These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 35047580)

  • 1. Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes.
    Hu X; Zhou R; Li H; Zhao X; Sun Y; Fan Y; Zhang S
    Front Cardiovasc Med; 2021; 8():805812. PubMed ID: 35047580
    [No Abstract]   [Full Text] [Related]  

  • 2. The Effects of Moderate Alcohol Consumption on Circulating Metabolites and Gut Microbiota in Patients With Coronary Artery Disease.
    Zhao X; Zhou R; Li H; Fan Y; Sun Y; Hu X; Zhang S
    Front Cardiovasc Med; 2021; 8():767692. PubMed ID: 34796220
    [No Abstract]   [Full Text] [Related]  

  • 3. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease.
    Yu JS; Youn GS; Choi J; Kim CH; Kim BY; Yang SJ; Lee JH; Park TS; Kim BK; Kim YB; Roh SW; Min BH; Park HJ; Yoon SJ; Lee NY; Choi YR; Kim HS; Gupta H; Sung H; Han SH; Suk KT; Lee DY
    Clin Transl Med; 2021 Dec; 11(12):e634. PubMed ID: 34965016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the gut microbiome and metabolism with coronary artery disease severity.
    Liu H; Chen X; Hu X; Niu H; Tian R; Wang H; Pang H; Jiang L; Qiu B; Chen X; Zhang Y; Ma Y; Tang S; Li H; Feng S; Zhang S; Zhang C
    Microbiome; 2019 Apr; 7(1):68. PubMed ID: 31027508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiome features and metabolites in non-alcoholic fatty liver disease among community-dwelling middle-aged and older adults.
    Zeng F; Su X; Liang X; Liao M; Zhong H; Xu J; Gou W; Zhang X; Shen L; Zheng JS; Chen YM
    BMC Med; 2024 Mar; 22(1):104. PubMed ID: 38454425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of Cigarette Smoking Status on Metabolomic and Gut Microbiota Profile in Male Patients With Coronary Artery Disease: A Multi-Omics Study.
    Hu X; Fan Y; Li H; Zhou R; Zhao X; Sun Y; Zhang S
    Front Cardiovasc Med; 2021; 8():766739. PubMed ID: 34778417
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease.
    Zhang Y; Xu J; Wang X; Ren X; Liu Y
    BMC Genomics; 2019 Nov; 20(1):862. PubMed ID: 31726978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-omics study reveals that statin therapy is associated with restoration of gut microbiota homeostasis and improvement in outcomes in patients with acute coronary syndrome.
    Hu X; Li H; Zhao X; Zhou R; Liu H; Sun Y; Fan Y; Shi Y; Qiao S; Liu S; Liu H; Zhang S
    Theranostics; 2021; 11(12):5778-5793. PubMed ID: 33897881
    [No Abstract]   [Full Text] [Related]  

  • 12. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.
    Raman M; Ahmed I; Gillevet PM; Probert CS; Ratcliffe NM; Smith S; Greenwood R; Sikaroodi M; Lam V; Crotty P; Bailey J; Myers RP; Rioux KP
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):868-75.e1-3. PubMed ID: 23454028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach.
    Stols-Gonçalves D; Mak AL; Madsen MS; van der Vossen EWJ; Bruinstroop E; Henneman P; Mol F; Scheithauer TPM; Smits L; Witjes J; Meijnikman AS; Verheij J; Nieuwdorp M; Holleboom AG; Levin E
    Gut Microbes; 2023 Dec; 15(1):2223330. PubMed ID: 37317027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota alterations are associated with functional outcomes in patients of acute ischemic stroke with non-alcoholic fatty liver disease.
    Yu G; Chen Q; Chen J; Liao X; Xie H; Zhao Y; Liu J; Sun J; Chen S
    Front Neurosci; 2023; 17():1327499. PubMed ID: 38178834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatoprotective Effects of
    Jin W; Cho S; Laxi N; Bao T; Dai L; Yu H; Qi R; Zhang J; Ba G; Fu M
    Molecules; 2022 May; 27(10):. PubMed ID: 35630624
    [No Abstract]   [Full Text] [Related]  

  • 17. Gut Microbiome and Serum Metabolome Alterations Associated with Isolated Dystonia.
    Ma L; Keng J; Cheng M; Pan H; Feng B; Hu Y; Feng T; Yang F
    mSphere; 2021 Aug; 6(4):e0028321. PubMed ID: 34346706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression.
    Zhou Y; Zheng T; Chen H; Li Y; Huang H; Chen W; Du Y; He J; Li Y; Cao J; Nie Y; Zhou Y
    Cell Physiol Biochem; 2018; 51(5):2123-2135. PubMed ID: 30522122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease.
    Long Q; Luo F; Li B; Li Z; Guo Z; Chen Z; Wu W; Hu M
    Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38407327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sesamolin Alleviates Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites in High-Fat and High-Fructose Diet-Fed Mice.
    Yu J; Sun H; Yang Y; Yan Y
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.